Free Cash Flow: $2.1 billion, up 10%. Net Debt to EBITDA Ratio: Close to 3 times. AUSTEDO Revenue: $1.7 billion, up 36%. AJOVY Revenue: Over $0.5 billion, up 18%. UZEDY Revenue: $117 million.

Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar ...

Te­va CEO Richard Fran­cis said he ex­pects sales growth to con­tin­ue for the com­pa­ny’s top-sell­ing drug Auste­do, even af­ter it be­comes sub­ject to new prices … ...

On January 17, 2025, the Centers for Medicare & Medicaid Services (CMS) released the names of 15 additional drugs to be included in the next round of drug price negotiation under Medicare Part D, ...

Officials plan to expand negotiations to include 15 more drugs in the next cycle and up to 20 more in following years. "Improving prescription drug affordability for Medicare enrollees is the core ...

The selected drugs treat conditions like diabetes, cancer and asthma WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce ...

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release. The ...

The first DLC pack for the fighting game has been revealed, and it's adding 11 new fighters to the mix. The Heroes of Justice Pack will be available to all season pass owners after it's released ...

The U.S. Department of Health and Human Services unveiled 15 additional drugs chosen for the Medicare Drug Price Negotiation Program on Friday. Many healthcare leaders are applauding the list of ...

Under the law, more drugs will be added to the negotiation process in coming years. The Centers for Medicare & Medicaid Services says the 15 drugs are Ozempic, Rybelsus and Wegovy; Trelegy Ellipta; ...

The Centers for Medicare and Medicaid Services says the 15 drugs are Ozempic, Rybelsus and Wegovy; Trelegy Ellipta; Xtandi; Pomalyst; Ibrance; Ofev; Linzess; Calquence; Austedo and Austedo XR ...